Recent progress of aptamer‒drug conjugates in cancer therapy.
10.1016/j.apsb.2023.01.017
- Author:
Jiaxuan HE
1
;
Qiao DUAN
1
;
Chunyan RAN
1
;
Ting FU
1
;
Yuan LIU
1
;
Weihong TAN
1
Author Information
1. The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Publication Type:Review
- Keywords:
Aptamer;
Aptamer‒drug conjugate;
Biotherapeutic drug;
Cancer therapy;
Drug delivery;
Nucleic acid drugs;
Small-molecule drug;
Therapeutic molecules
- From:
Acta Pharmaceutica Sinica B
2023;13(4):1358-1370
- CountryChina
- Language:English
-
Abstract:
Aptamers are single-stranded DNA or RNA sequences that can specifically bind with the target protein or molecule via specific secondary structures. Compared to antibody-drug conjugates (ADC), aptamer‒drug conjugate (ApDC) is also an efficient, targeted drug for cancer therapy with a smaller size, higher chemical stability, lower immunogenicity, faster tissue penetration, and facile engineering. Despite all these advantages, several key factors have delayed the clinical translation of ApDC, such as in vivo off-target effects and potential safety issues. In this review, we highlight the most recent progress in the development of ApDC and discuss solutions to the problems noted above.
